Aethlon Medical reports biomarker shifts in second cohort of Hemopurifier cancer trialPUBT·Jul 13 at 07:06 AMAEMD+17.10%
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier® | AEMD Stock NewsStockTitan·Jul 12 at 11:01 PMAEMD+17.10%
Aethlon Medical Raises ~$4.0 Million in Registered Offering Priced at $0.71; Maxim Group as AgentTradingView·Jul 8 at 05:03 AMAEMD+17.10%
Aethlon Medical prices $4 million offering with warrants exercisable at $0.71 on shareholder approvalPUBT·Jul 6 at 08:28 AMAEMD+17.10%
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules | AEMD Stock NewsStockTitan·Jul 6 at 12:25 AMAEMD+17.10%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Jul 1 at 04:05 PMCMMB+1.31%CRIS+1.21%
Aethlon Medical shares are trading lower after the company filed a prospectus for a mixed shelf offering.benzinga_article·Jul 1 at 08:17 AMAEMD+17.10%
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier® | AEMD Stock NewsStockTitan·Jun 25 at 11:01 PMAEMD+17.10%
